Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


03.09.2018

1 Am J Clin Pathol
1 Ann Oncol
4 Arch Bronconeumol
8 BMC Cancer
1 Cancer Sci
1 Clin Cancer Res
2 Clin Lung Cancer
2 Int J Cancer
2 Int J Oncol
1 Int J Radiat Oncol Biol Phys
4 J Clin Oncol
1 J Thorac Cardiovasc Surg
8 J Thorac Oncol
1 Lancet Respir Med
1 Lung Cancer
1 N Engl J Med
2 Oncol Rep
1 Oncologist
3 PLoS One
4 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. VIDARSDOTTIR H, Tran L, Nodin B, Jirstrom K, et al
    Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases.
    Am J Clin Pathol. 2018 Aug 30. pii: 5086670. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. KRON A, Alidousty C, Scheffler M, Merkelbach-Bruse S, et al
    Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5079835. doi: 10.1093.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. LOUZA GF, Zanetti G, Marchiori E
    Neurofibromatosis Type I With Pulmonary Involvement.
    Arch Bronconeumol. 2018;54:106-107.
    PubMed     Text format    

  4. GUTIERREZ-DOMINGO A, Gutierrez-Domingo I, Gallardo-Rodriguez KM
    Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis.
    Arch Bronconeumol. 2018;54:108-109.
    PubMed     Text format    

  5. KUMAR A, Cherian SV, Farver C, Mehta AC, et al
    Pulmonary Meningotheliomatosis.
    Arch Bronconeumol. 2018;54:104-105.
    PubMed     Text format    

  6. DELGADO TORRALBO JA, Garcia Gomez LC, Sanchez Varilla JM
    Unilateral lung infiltrate: A rare form of presentation of primary pulmonary lymphoma.
    Arch Bronconeumol. 2018;54:103-104.
    PubMed     Text format    


    BMC Cancer

  7. RYSKA A, Berzinec P, Brcic L, Cufer T, et al
    NSCLC molecular testing in Central and Eastern European countries.
    BMC Cancer. 2018;18:269.
    PubMed     Text format     Abstract available

  8. YORITA K, Tsuji K, Takano Y, Kuroda N, et al
    Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report.
    BMC Cancer. 2018;18:300.
    PubMed     Text format     Abstract available

  9. YAO D, Zhang L, Wu PL, Gu XL, et al
    Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.
    BMC Cancer. 2018;18:281.
    PubMed     Text format     Abstract available

  10. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Text format     Abstract available

  11. LEE DW, Lee KH, Kim HJ, Kim TY, et al
    A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    BMC Cancer. 2018;18:252.
    PubMed     Text format     Abstract available

  12. DE FONSEKA D, Arnold DT, Stadon L, Morley A, et al
    A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    BMC Cancer. 2018;18:199.
    PubMed     Text format     Abstract available

  13. DEMUTH C, Madsen AT, Weber B, Wu L, et al
    The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    BMC Cancer. 2018;18:191.
    PubMed     Text format     Abstract available

  14. BRIZZI MP, La Salvia A, Tampellini M, Sonetto C, et al
    Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
    BMC Cancer. 2018;18:311.
    PubMed     Text format     Abstract available


    Cancer Sci

  15. XU S, Lam SK, Cheng PN, Ho JC, et al
    Recombinant human arginase induces apoptosis via oxidative stress and cell cycle arrest in small cell lung cancer.
    Cancer Sci. 2018 Aug 28. doi: 10.1111/cas.13782.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  16. RICHARD C, Fumet JD, Chevrier S, Derangere V, et al
    Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.
    Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-1940.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  17. REN S, Rivard CJ, Yu H, Genova C, et al
    A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Clin Lung Cancer. 2018;19:450-456.
    PubMed     Text format     Abstract available

  18. BERRY MF, Canchola AJ, Gensheimer MF, Gomez SL, et al
    Factors Associated With Treatment of Clinical Stage I Non-Small-cell Lung Cancer: A Population-based Analysis.
    Clin Lung Cancer. 2018;19:e745-e758.
    PubMed     Text format     Abstract available


    Int J Cancer

  19. LEHMAN JM, Hoeksema MD, Staub J, Qian J, et al
    Somatostatin Receptor 2 signaling promotes growth and tumor survival in Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31771.
    PubMed     Text format     Abstract available

  20. JIANG Y, Dai H, Li Y, Yin J, et al
    PARP Inhibitors Synergize with Gemcitabine by Potentiating DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31770.
    PubMed     Text format     Abstract available


    Int J Oncol

  21. KAMINSKA K, Czarnecka AM, Khan MI, Fendler W, et al
    Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis.
    Int J Oncol. 2018;52:768-786.
    PubMed     Text format     Abstract available

  22. SUETSUGU T, Koshizuka K, Seki N, Mizuno K, et al
    Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells.
    Int J Oncol. 2018;52:913-924.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  23. YANG P, Xu T, Gomez DR, Deng W, et al
    Patterns of Local-Regional Failure after Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Aug 27. pii: S0360-3016(18)33637.
    PubMed     Text format     Abstract available


    J Clin Oncol

  24. WU YL, Zhang L, Kim DW, Liu X, et al
    Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326.
    PubMed     Text format     Abstract available

  25. WANG YN, Yao S, Wang CL, Li MS, et al
    Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.
    J Clin Oncol. 2018 Aug 27:JCO2018787101. doi: 10.1200/JCO.2018.78.7101.
    PubMed     Text format     Abstract available

  26. DE RUYSSCHER DKM, Decaluwe H
    4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?
    J Clin Oncol. 2018 Aug 27:JCO2018793299. doi: 10.1200/JCO.2018.79.3299.
    PubMed     Text format    

  27. REUNGWETWATTANA T, Nakagawa K, Cho BC, Cobo M, et al
    CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  28. LIN J, Fernandez F
    Indications for invasive mediastinal staging for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2018 Jul 21. pii: S0022-5223(18)31872.
    PubMed     Text format    


    J Thorac Oncol

  29. DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
    Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    J Thorac Oncol. 2018;13:e169-e172.
    PubMed     Text format    

  30. XU YJ, Shi ZL, Wang Z, Du L, et al
    Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e165-e168.
    PubMed     Text format    

  31. MORO M, Caiola E, Ganzinelli M, Zulato E, et al
    Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
    PubMed     Text format     Abstract available

  32. MARINO M, Visca P, Ottaviano M
    PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
    J Thorac Oncol. 2018;13:1239-1241.
    PubMed     Text format    

  33. JIN B, Chuang X, Liu Y
    Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e174-e177.
    PubMed     Text format    

  34. WALRAVEN I, Kwint M, Belderbos J
    The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e181-e182.
    PubMed     Text format    

  35. MO X, Xu-Welliver M
    Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e182-e183.
    PubMed     Text format    

  36. SWAMI U, Smith M, Zhang J
    Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    J Thorac Oncol. 2018;13:e183-e184.
    PubMed     Text format    


    Lancet Respir Med

  37. YUE D, Xu S, Wang Q, Li X, et al
    Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Lancet Respir Med. 2018 Aug 24. pii: S2213-2600(18)30277.
    PubMed     Text format     Abstract available


    Lung Cancer

  38. DICKHOFF C, Dahele M
    In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
    PubMed     Text format    


    N Engl J Med


  39. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed     Text format    


    Oncol Rep

  40. HE X, Zhang C, Shi C, Lu Q, et al
    Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers.
    Oncol Rep. 2018;39:929-938.
    PubMed     Text format     Abstract available

  41. ISHIWATA T, Iwasawa S, Ebata T, Fan M, et al
    Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lung.
    Oncol Rep. 2018;39:1148-1154.
    PubMed     Text format     Abstract available


    Oncologist

  42. XIONG L, Li R, Sun J, Lou Y, et al
    Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
    Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120.
    PubMed     Text format     Abstract available


    PLoS One

  43. YANO Y, Kurebe H, Edahiro R, Hosono Y, et al
    Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    PLoS One. 2018;13:e0203070.
    PubMed     Text format     Abstract available

  44. LEE DH, Tsao MS, Kambartel KO, Isobe H, et al
    Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    PLoS One. 2018;13:e0202865.
    PubMed     Text format     Abstract available

  45. SCHAD F, Thronicke A, Steele ML, Merkle A, et al
    Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    PLoS One. 2018;13:e0203058.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  46. LI L, Li JC, Yang H, Zhang X, et al
    Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis.
    Proc Natl Acad Sci U S A. 2018 Aug 29. pii: 1806219115.
    PubMed     Text format     Abstract available

  47. WU L, Zhang H, Jiang Y, Gallo RC, et al
    Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
    Proc Natl Acad Sci U S A. 2018;115:E4453-E4462.
    PubMed     Text format     Abstract available

  48. XU H, Lee MS, Tsai PY, Adler AS, et al
    Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis.
    Proc Natl Acad Sci U S A. 2018;115:4228-4233.
    PubMed     Text format     Abstract available

  49. ZHAO L, Huang S, Mei S, Yang Z, et al
    Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
    Proc Natl Acad Sci U S A. 2018;115:E3673-E3681.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: